I. Latorzeff
46 Papers
216 Citations
I. Latorzeff is an academic researcher. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 9, co-authored 44 publications.
Chat about Author
Papers
Radiothérapie postopératoire des cancers de la prostate
Pierre Richaud,P. Sargos,B. Henriques de Figueiredo,I. Latorzeff,P. Mongiat-Artus,N. Houede,L. Salomon,H. Wallerand +7 more
TL;DR: The GETUG AFU 17 trial will provide answers to the question of the optimal moment for postoperative radiotherapy for pT3-4 R1 pN0 Nx patients with the objective of comparing an immediate treatment to a differed early treatment initiated at biological recurrence.
51
Apports de la radiothérapie avec modulation d’intensité guidée par l’image dans les cancers prostatiques
TL;DR: L’arc-RCMI est une nouvelle modalite de RCMI particulierement interessante, car diminuant fortement the duree d’irradiation.
40
Radiothérapie externe des cancers prostatiques
TL;DR: Les techniques de radiotherapie externe prostatique sont decrites, tant en cas d’irradiation de la prostate en place qu’apres prostatectomie, incluant ou non les aires ganglionnaires pelviennes.
26
Radiothérapie des métastases cérébrales
I. Latorzeff,Delphine Antoni,S Gaudaire-Josset,Loïc Feuvret,A Tallet-Richard,Gilles Truc,Georges Noël +6 more
TL;DR: La radiotherapie des metastases cerebrales en conditions stereotaxiques a supplante l’irradiation encephalique en totalite tant pour les patients atteints de metastases en place que pour ceux qui ont ete operes.
24
Dose constraints for moderate hypofractionated radiotherapy for prostate cancer The French genito-urinary group (GETUG) recommendations
J Langrand-Escure,R. de Crevoisier,C Llagostera,Gilles Créhange,G. Delaroche,Caroline Lafond,C Bonin,F Bideault,P. Sargos,S. Belhomme,David Pasquier,I. Latorzeff,Stéphane Supiot,Christophe Hennequin +13 more
TL;DR: In this paper, the French Genito-Urinary Group (GETUG) provides recommendations for daily practice of moderate hypofractionated radiotherapy for prostate cancer, with indications, dose, fractionation, pre-treatment planning, volume of interest delineation (target volume and organs at risk), margins, dose constraints and radiotherapy techniques.
23